Semaglutide For protecting the heart, semaglutide is the safer bet right now
Addressing Metabolic Dysfunction as an Independent Cancer Risk Factor Accumulating evidence positions metabolic dysfunction characterised by insulin resistance, hepatic steatosis, dyslipidaemia, and visceral adiposity as a more powerful and proximate predictor of cancer risk than elevated body weight alone
By activating both of these receptors, tirzepatide promotes weight loss more effectively than traditional treatments targeting only the GLP-1 receptor
Phase I and II clinical trials corroborate these findings, showing dose-dependent weight loss, reductions in Glycated Hemoglobin (HbA1c) levels, and improvements in liver steatosis and diabetic kidney disease
You should not use GLP-1 medications if you have: Personal or family history of medullary thyroid cancer Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Previous severe allergic reaction to semaglutide or liraglutide Current pregnancy or planning to become pregnant History of pancreatitis (requires careful evaluation) Severe gastrointestinal disease Additionally, these medications are not typically recommended for patients under 18 years old, though Saxenda has some pediatric approval for adolescents 12 and older with obesity
